Z. Shao

发表

Wanqing Chen, L. Fan, K. Strasser-Weippl, 2014, The Lancet. Oncology.

Different Distribution of Breast Cancer Subtypes in Breast Ductal Carcinoma in situ (DCIS), DCIS with Microinvasion, and DCIS with Invasion Component

Keda Yu, Z. Shao, L. Wu, 2011, Annals of Surgical Oncology.

ERβ exerts multiple stimulative effects on human breast carcinoma cells

Jiong Wu, Z. Shao, Jiong Wu, 2004, Oncogene.

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

C. Perou, E. Winer, J. Forbes, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Different annual recurrence pattern between lumpectomy and mastectomy: implication for breast cancer surveillance after breast-conserving surgery.

Keda Yu, Z. Shao, Shuang Li, 2011, The oncologist.

Addition of adjuvant tamoxifen to cyclophosphamide, methotrexate and 5-fluorouracil for premenopausal women with oestrogen receptor-positive breast cancer.

Z. Shao, Zhen-zhou Shen, Yi-feng Hou, 2003, Asian journal of surgery.

Ubiquitination/deubiquitination and acetylation/deacetylation: Making DNMT1 stability more coordinated

Z. Shao, Q. Hong, 2011, Acta Pharmacologica Sinica.

Anthracycline-free or short-term regimen as adjuvant chemotherapy for operable breast cancer: A phase III randomized non-inferiority trial

F. Bertucci, G. Lippi, L. Fan, 2021, The Lancet regional health. Western Pacific.

Tailoring Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A CYP2D6 Multiple-Genotype-Based Modeling Analysis and Validation

Keda Yu, Z. Shao, A. Huang, 2010, PloS one.

Involvement of MyoD and c-myb in regulation of basal and estrogen-induced transcription activity of the BRCA1 gene

W. Jin, Z. Shao, Jiong Wu, 2011, Breast Cancer Research and Treatment.

Evaluating the performance of models for predicting the BRCA germline mutations in Han Chinese familial breast cancer patients

Z. Shao, Jiong Wu, Zhen-zhou Shen, 2009, Breast Cancer Research and Treatment.

The analysis of BRCA1 mutations in eastern Chinese patients with early onset breast cancer and affected relatives

Z. Shao, Jiong Wu, Zhen-zhou Shen, 2003, Human mutation.

Kinetics Comparisons of Mammalian Atg4 Homologues Indicate Selective Preferences toward Diverse Atg8 Substrates*

Z. Shao, Xiao-Ming Yin, Min Li, 2010, The Journal of Biological Chemistry.

Some common mutations of RAD50 and NBS1 in western populations do not contribute significantly to Chinese non-BRCA1/2 hereditary breast cancer

W. Jin, Z. Shao, W. Yin, 2010, Breast Cancer Research and Treatment.

Cyclophosphamide-Free Adjuvant Chemotherapy for Ovarian Protection in Young Women With Breast Cancer: A Randomized Phase 3 Trial

Keda Yu, Z. Shao, Xi-Yu Liu, 2021, Journal of the National Cancer Institute.

Influence of delayed initiation of adjuvant chemotherapy on breast cancer survival is subtype-dependent

L. Fan, Keda Yu, Z. Shao, 2016, Oncotarget.

The early-stage triple-negative breast cancer landscape derives a novel prognostic signature and therapeutic target

Xiao-En Xu, Z. Shao, Yizhou Jiang, 2022, Breast Cancer Research and Treatment.

Pharmacological Disruption of the MTDH-SND1 Complex Enhances Tumor Antigen Presentation and Synergizes with Anti-PD-1 Therapy in Metastatic Breast Cancer

Yibin Kang, Z. Shao, Yong Wei, 2021, Nature Cancer.

Pregnancy-associated breast cancer in women from Shanghai: risk and prognosis

L. Fan, K. Strasser-Weippl, Junjie Li, 2014, Breast Cancer Research and Treatment.

Is breast cancer in young Asian women more aggressive than in Caucasians? A cross-sectional analysis

L. Fan, Z. Shao, S. Steurer, 2013, Tumor Biology.

A predictor of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer patients with the DNA repair genes

Z. Shao, G. Lang, Jin-xiu Shi, 2021, Annals of translational medicine.

Breast cancer screening and early diagnosis in Chinese women

Z. Shao, Yizhou Jiang, M. Mo, 2022, Cancer biology & medicine.

RAD51 135G>C does not modify breast cancer risk in non-BRCA1/2 mutation carriers: evidence from a meta-analysis of 12 studies

L. Fan, Keda Yu, Z. Shao, 2011, Breast Cancer Research and Treatment.

Lack of an association between a functional polymorphism in the interleukin-6 gene promoter and breast cancer risk: a meta-analysis involving 25,703 subjects

L. Fan, Keda Yu, Z. Shao, 2010, Breast Cancer Research and Treatment.

Test of Hardy–Weinberg equilibrium in breast cancer case-control studies: an issue may influence the conclusions

L. Fan, Keda Yu, Z. Shao, 2009, Breast Cancer Research and Treatment.

Serum HER2 levels predict treatment efficacy and prognosis in patients with HER2-positive breast cancer undergoing neoadjuvant treatment.

Z. Shao, Hui Zheng, R. Lu, 2021, Gland surgery.

A Multiomics Signature Highlights Alterations Underlying Homologous Recombination Deficiency in Triple-Negative Breast Cancer

W. Peng, Z. Shao, Yi Xiao, 2022, Annals of Surgical Oncology.

Determining the Optimal (Neo)Adjuvant Regimen for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Regarding Survival Outcome: A Network Meta-Analysis

Keda Yu, Z. Shao, Yu-Wen Cai, 2022, Frontiers in Immunology.

Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial

Xin Hu, L. Fan, Junjie Li, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Concordance of Hormone Receptor Status and BRCA1/2 Mutation Among Women With Synchronous Bilateral Breast Cancer

Z. Shao, G. Lang, A. Cao, 2020, Frontiers in Oncology.

Polymorphism rs4919510:C>G in Mature Sequence of Human MicroRNA-608 Contributes to the Risk of HER2-Positive Breast Cancer but Not Other Subtypes

L. Fan, Keda Yu, Z. Shao, 2012, PloS one.

A Multiomics Signature Highlights Alterations Underlying Homologous Recombination Deficiency in Triple-Negative Breast Cancer

W. Peng, Z. Shao, Yizhou Jiang, 2022, Annals of Surgical Oncology.

Genomic features of rapid versus late relapse in triple negative breast cancer

E. Winer, Leming Shi, B. Ramaswamy, 2021, BMC cancer.

The spectrum of BRCA mutations and characteristics of BRCA‐associated breast cancers in China: Screening of 2,991 patients and 1,043 controls by next‐generation sequencing

Xin Hu, Menghong Sun, Keda Yu, 2017, International journal of cancer.

Genistein inhibits proliferation similarly in estrogen receptor‐positive and negative human breast carcinoma cell lines characterized by P21WAF1/CIP1 induction, G2/M arrest, and apoptosis

Z. Shao, S. Barsky, J. Fontana, 1998, Journal of cellular biochemistry.

Effect of functional genetic variants in chemokine decoy receptors on the recurrence risk of breast cancer

Keda Yu, Z. Shao, C. Yang, 2018, Cancer medicine.

Differential Effects of Endoplasmic Reticulum Stress-induced Autophagy on Cell Survival*

D. Stolz, Z. Shao, Wentao Gao, 2007, Journal of Biological Chemistry.

A cross-sectional study of elderly Asian and European women with primary operable breast cancer aged 70 and older. Are there differences?

Z. Shao, G. Di, S. Steurer, 2012, Maturitas.

Efficacy and Safety of Docetaxel Combined With Oxaliplatin as a Neoadjuvant Chemotherapy Regimen for Chinese Triple-Negative Local Advanced Breast Cancer Patients: A Prospective, Open, and Unicentric Phase II Clinical Trial

Z. Shao, Guangyu Liu, Jiong Wu, 2013, American journal of clinical oncology.

Dominant-negative E-cadherin inhibits the invasiveness of inflammatory breast cancer cells in vitro

Z. Shao, Jiong Wu, Zhen-zhou Shen, 2006, Journal of Cancer Research and Clinical Oncology.

Polymorphisms in the kinesin-like factor 1 B gene and risk of epithelial ovarian cancer in Eastern Chinese women

Menghong Sun, Q. Wei, Keda Yu, 2015, Tumor Biology.

ERβ and PEA3 co-activate IL-8 expression and promote the invasion of breast cancer cells

W. Jin, Z. Shao, N. Mukaida, 2011, Cancer biology & therapy.

UHRF1 is associated with epigenetic silencing of BRCA1 in sporadic breast cancer

W. Jin, Z. Shao, Jiong Wu, 2010, Breast Cancer Research and Treatment.

Radiogenomic analysis reveals tumor heterogeneity of triple-negative breast cancer

Z. Shao, Dan Zhang, Yizhou Jiang, 2022, Cell reports. Medicine.

UHRF1 inhibits MDR1 gene transcription and sensitizes breast cancer cells to anticancer drugs

W. Jin, Z. Shao, Jin-Ming Yang, 2010, Breast Cancer Research and Treatment.

Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer

Z. Shao, Leiping Wang, Biyun Wang, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Stabilization of CCDC102B by Loss of RACK1 Through the CMA Pathway Promotes Breast Cancer Metastasis via Activation of the NF-κB Pathway

Z. Shao, Jiong Wu, Jia-jian Chen, 2022, Frontiers in Oncology.

Transcriptome Analysis Derives a Novel Prognostic 7-mRNA Signature in Early-Stage Triple-Negative Breast Cancer

Xiao-En Xu, Z. Shao, Yizhou Jiang, 2021 .

Genetic Polymorphisms in the DNA Repair Enzyme ERCC2 and Breast Tumour Risk in a Chinese Population

W. Jin, Z. Shao, G. Di, 2008, The Journal of international medical research.

Radiogenomics Analysis Reveals Tumor Heterogeneity of Triple-Negative Breast Cancer

Z. Shao, H. Wang, L. Jiang, 2021 .

Omission of axillary surgery for ipsilateral breast tumor recurrence with negative nodes after previous breast-conserving surgery: is it oncologically safe?

Junjie Li, Keda Yu, Z. Shao, 2022, Breast Cancer Research and Treatment.

Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Early Triple-Negative Breast Cancer-Reply.

Keda Yu, Z. Shao, 2021, JAMA oncology.

A comprehensive genomic and transcriptomic dataset of triple-negative breast cancers

Leming Shi, Yuanting Zheng, Z. Shao, 2022, Scientific Data.

Survival benefit from response-guided approach: a direct effect of more effective cytotoxic regimens or an indirect effect of chemotherapy-induced amenorrhea?

Keda Yu, Z. Shao, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Influence of a family history of breast and/or ovarian cancer on breast cancer outcomes.

Z. Shao, Guangyu Liu, Jiong Wu, 2011, Experimental and therapeutic medicine.

Radiomics features for assessing tumor-infiltrating lymphocytes correlate with molecular traits of triple-negative breast cancer

Z. Shao, Yan Chen, Yi Xiao, 2022, Journal of Translational Medicine.

Expression of estrogen receptors in estrogen receptor–negative human breast carcinoma cells: Modulation of epidermal growth factor‐receptor (EGF‐R) and transforming growth factor α (TGFα) gene expression

Z. Shao, J. Fontana, Xiao-su Li, 1994, Journal of cellular biochemistry.

SDF-1 expression and tumor-infiltrating lymphocytes identify clinical subtypes of triple-negative breast cancer with different responses to neoadjuvant chemotherapy and survival

Z. Shao, Y. Gong, P. Ji, 2022, Frontiers in Immunology.

Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy.

Z. Shao, Da-Qiang Li, Wei Huang, 2022, Cell metabolism.

Enhanced Expression of LKB1 in Breast Cancer Cells Attenuates Angiogenesis, Invasion, and Metastatic Potential

Z. Shao, G. Di, Zhen-zhou Shen, 2006, Molecular Cancer Research.

Omission of axillary surgery for ipsilateral breast tumor recurrence with negative nodes after previous breast-conserving surgery: is it oncologically safe?

Junjie Li, Keda Yu, Z. Shao, 2022, Breast Cancer Research and Treatment.

Mutation screening of breast cancer susceptibility genes in Chinese high-risk families: the results will develop the genetic testing strategy in China

Z. Shao, Zhen Hu, A. Cao, 2010, Breast Cancer Research and Treatment.

Accuracy of ultrasound-guided targeted fine-needle aspiration in assessing nodal response in node-positive breast cancer after neoadjuvant chemotherapy: a prospective feasibility study.

Z. Shao, Huai-liang Wu, Guangrong Liu, 2022, The British journal of surgery.

Initiation, evolution, phenotype and outcome of BRCA1 and BRCA2 mutation-associated breast cancer

Keda Yu, Z. Shao, 2012, Nature Reviews Cancer.

Estrogen Receptor (ER) β or p53 Attenuates ERα-mediated Transcriptional Activation on the BRCA2 Promoter*

W. Jin, P. Miron, Z. Shao, 2008, Journal of Biological Chemistry.

Immunosuppressive lncRNA LINC00624 promotes tumor progression and therapy resistance through ADAR1 stabilization

Z. Shao, Shenglin Huang, Liyi Zhang, 2022, Journal for ImmunoTherapy of Cancer.

Uncovering the molecular subtypes of triple-negative breast cancer with a noninvasive radiomic methodology

Z. Shao, Yizhou Jiang, Yi Xiao, 2022, Cell reports. Medicine.

Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients

Xin Hu, Z. Shao, Wei Huang, 2018, Nature Communications.

Technological advances in cancer immunity: from immunogenomics to single-cell analysis and artificial intelligence

Z. Shao, Yizhou Jiang, D. Ma, 2021, Signal Transduction and Targeted Therapy.

Genetic variants in oxidative stress-related genes predict chemoresistance in primary breast cancer: a prospective observational study and validation.

L. Fan, Keda Yu, Z. Shao, 2012, Cancer research.

Functional polymorphisms, altered gene expression and genetic association link NRH:quinone oxidoreductase 2 to breast cancer with wild-type p53.

L. Fan, Keda Yu, Z. Shao, 2009, Human molecular genetics.

The microbial metabolite trimethylamine N-oxide promotes antitumor immunity in triple-negative breast cancer.

Xin Hu, Z. Shao, Da-Qiang Li, 2022, Cell metabolism.

Current evidence on the relationship between polymorphisms in the COX-2 gene and breast cancer risk: a meta-analysis

Wen-Huan Xu, Chen Yang, L. Fan, 2010, Breast Cancer Research and Treatment.

Copy number amplification of ENSA promotes the progression of triple-negative breast cancer via cholesterol biosynthesis

Keda Yu, Z. Shao, Jin-Yu Ge, 2022, Nature communications.

Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives

Z. Shao, Jiong Wu, G. Di, 2009, Breast Cancer Research and Treatment.

Genomic features of rapid versus late relapse in triple negative breast cancer

E. Winer, Leming Shi, B. Ramaswamy, 2021, BMC Cancer.

Tumor-derived Jagged1 promotes cancer progression through immune evasion.

Yuan Zhang, Yibin Kang, Z. Shao, 2022, Cell reports.

Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer

Xin Hu, Xiao-En Xu, Keda Yu, 2016, Breast Cancer Research.

LINC02273 drives breast cancer metastasis by epigenetically increasing AGR2 transcription

Z. Shao, Jiong Wu, Shenglin Huang, 2019, Molecular Cancer.

Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response

Z. Shao, Yi Xiao, Yizhou Jiang, 2021, Journal of Hematology & Oncology.

Resistance to antibody‐drug conjugates in breast cancer: mechanisms and solutions

Keda Yu, Z. Shao, Ying-ying Xu, 2022, Cancer communications.

Proteome-centric cross-omics characterization and integrated network analyses of triple-negative breast cancer.

Z. Shao, Da-Qiang Li, Peng-Yuan Yang, 2022, Cell reports.

MicroRNA-200a confers chemoresistance by antagonizing TP53INP1 and YAP1 in human breast cancer

Z. Shao, G. Di, Q. Hong, 2018, BMC Cancer.

MicroRNA-200a Promotes Anoikis Resistance and Metastasis by Targeting YAP1 in Human Breast Cancer

Z. Shao, Jiong Wu, G. Di, 2013, Clinical Cancer Research.

Small Molecule Inhibitors that Disrupt the MTDH-SND1 Complex Suppress Breast Cancer Progression and Metastasis

Yibin Kang, Z. Shao, J. Bertino, 2021, Nature Cancer.

TIEG1 Inhibits Breast Cancer Invasion and Metastasis by Inhibition of Epidermal Growth Factor Receptor (EGFR) Transcription and the EGFR Signaling Pathway

Jiong Wu, W. Jin, Z. Shao, 2011, Molecular and Cellular Biology.

p 53 Mutation in Plasma DNA and Its Prognostic Value in Breast Cancer Patients 1

Z. Shao, M. Nguyen, Jun Wu, 2001 .

The prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives

Z. Shao, Jiong Wu, G. Di, 2009, Breast Cancer Research and Treatment.

Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer

Xin Hu, Xiao-En Xu, Keda Yu, 2016, Clinical Cancer Research.

DualCharacteristics ofNovelHER2KinaseDomain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer

Xin Hu, Xiao-En Xu, Keda Yu, 2016 .

Combined Single‐Cell and Spatial Transcriptomics Reveal the Metabolic Evolvement of Breast Cancer during Early Dissemination

Keda Yu, Z. Shao, Tong Liu, 2023, Advanced science.

Large‐scale genomic sequencing reveals adaptive opportunity of targeting mutated‐PI3Kα in early and advanced HER2‐positive breast cancer

Xin Hu, Z. Shao, Li Chen, 2021, Clinical and translational medicine.

Breast cancer in a transitional society over 18 years: trends and present status in Shanghai, China

L. Fan, Keda Yu, Z. Shao, 2009, Breast Cancer Research and Treatment.

Germline Genetic Variants Disturbing the Let-7/LIN28 Double-Negative Feedback Loop Alter Breast Cancer Susceptibility

L. Fan, Keda Yu, Z. Shao, 2011, PLoS genetics.

Neddylation Inactivation Facilitates FOXO3a Nuclear Export to Suppress Estrogen Receptor Transcription and Improve Fulvestrant Sensitivity

Hefen Sun, Xin Hu, Keda Yu, 2019, Clinical Cancer Research.

Sox17, the canonical Wnt antagonist, is epigenetically inactivated by promoter methylation in human breast cancer

Z. Shao, Wei Huang, De-Yuan Fu, 2010, Breast Cancer Research and Treatment.

Multiple cancer susceptible genes sequencing in BRCA-negative breast cancer with high hereditary risk

Xin Hu, Z. Shao, Wei Huang, 2020, Annals of translational medicine.

The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified

Z. Shao, Jiong Wu, G. Di, 2008, Breast Cancer Research and Treatment.

The early-stage triple-negative breast cancer landscape derives a novel prognostic signature and therapeutic target

Xiao-En Xu, Z. Shao, Yizhou Jiang, 2021, Breast Cancer Research and Treatment.

Frequent epigenetic inactivation of the receptor tyrosine kinase EphA5 by promoter methylation in human breast cancer.

Wei Huang, Wen-Tao Yang, Z. Shao, 2010, Human pathology.

p21/waf1/cip1 and mdm‐2 expression in breast carcinoma patients as related to prognosis

Z. Shao, J. Fontana, Jun Wu, 1997, International journal of cancer.

Insulin‐like growth factor‐binding protein enhancement of insulin‐like growth factor‐i (IGF‐I)–mediated DNA synthesis and IGF‐I binding in a human breast carcinoma cell line

Z. Shao, C. Roberts, D. Leroith, 1994, Journal of cellular physiology.

Homologous recombination deficiency and glycolysis‐related pathway in adjuvant chemotherapy for triple‐negative breast cancer: A genomic landscape and biomarker assessment of the PATTERN trial

Keda Yu, Z. Shao, D. Ma, 2021, Clinical and translational medicine.

PDSS1-Mediated Activation of CAMK2A-STAT3 Signaling Promotes Metastasis in Triple-Negative Breast Cancer

Xin Hu, Z. Shao, B. Lian, 2021, Cancer Research.

Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer

L. Fan, Keda Yu, Z. Shao, 2020, JAMA oncology.

Regulation of insulin‐like growth factor‐binding‐protein‐1, 2, 3, 4, 5, and 6: Synthesis, secretion, and gene expression in estrogen receptor‐negative human breast carcinoma cells

Z. Shao, C. Roberts, D. Leroith, 1993, Journal of cellular physiology.

Enhanced Expression of Rab27A Gene by Breast Cancer Cells Promoting Invasiveness and the Metastasis Potential by Secretion of Insulin-Like Growth Factor-II

Z. Shao, Z. Shen, F. Wang, 2008, Molecular Cancer Research.

Identification of the functional role of AF1Q in the progression of breast cancer

W. Jin, Z. Shao, Jiong Wu, 2008, Breast Cancer Research and Treatment.

The tumor suppressor gene LKB1 is associated with prognosis in human breast carcinoma.

Z. Shao, F. Lan, Zan Shen, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Significance of Apoptosis and Apoptotic‐Related Proteins, Bcl‐2, and Bax in Primary Breast Cancer

Z. Shao, Jiong Wu, S. Barsky, 2000, The Breast Journal.

Dimerization of MORC2 through its C-terminal coiled-coil domain enhances chromatin dynamics and promotes DNA repair

Z. Shao, Da-Qiang Li, Z. Shao, 2019, Cell Communication and Signaling.

Invasive micropapillary carcinoma of the breast had no difference in prognosis compared with invasive ductal carcinoma: a propensity-matched analysis

Keda Yu, Z. Shao, Jingping Peng, 2019, Scientific Reports.

Nomogram for predicting preoperative lymph node involvement in patients with invasive micropapillary carcinoma of breast: a SEER population-based study

Xin Hu, Z. Shao, Z. Shao, 2018, BMC Cancer.

The Tumor Suppressor Gene LKB 1 Is Associated with Prognosis in Human Breast Carcinoma 1

Z. Shao, F. Lan, Zan Shen, 2002 .

A pri-miR-218 variant and risk of cervical carcinoma in Chinese women

Menghong Sun, Q. Wei, Keda Yu, 2013, BMC Cancer.

No association between a progesterone receptor gene promoter polymorphism (+331G>A) and breast cancer risk in Caucasian women: evidence from a literature-based meta-analysis

Keda Yu, Z. Shao, Aoxiang Chen, 2010, Breast Cancer Research and Treatment.

Bidirectional crosstalk between therapeutic cancer vaccines and the tumor microenvironment: Beyond tumor antigens

Z. Shao, Siwei Zhang, Yizhou Jiang, 2022, Fundamental research.

Integrated analysis reveals the molecular features of fibrosis in triple-negative breast cancer

Z. Shao, G. Di, Yizhou Jiang, 2022, Molecular therapy oncolytics.

Breast cancer patients with estrogen receptor-negative/progesterone receptor-positive tumors: being younger and getting less benefit from adjuvant tamoxifen treatment

Keda Yu, Z. Shao, Guangyu Liu, 2008, Journal of Cancer Research and Clinical Oncology.

ASO Author Reflections: Deeper Insight into Therapeutic Implications and Non-invasive Detection of Homologous Recombination Deficiency in Triple-Negative Breast Cancer: Results from a Multi-omics Cohort Study

W. Peng, Z. Shao, Yizhou Jiang, 2022, Annals of Surgical Oncology.

MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer

Xin Hu, Xiao-En Xu, Z. Shao, 2021, Journal for ImmunoTherapy of Cancer.

Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma

Z. Shao, Jiong Wu, G. Di, 2004, Breast Cancer Research and Treatment.

Association of HER-2 copy number and HER-2/CEP-17 ratio with neoadjuvant taxane-containing chemotherapy sensitivity in locally advanced breast cancer.

Keda Yu, Z. Shao, Guangyu Liu, 2012, The oncologist.

RAD50 and NBS1 are not likely to be susceptibility genes in Chinese non-BRCA1/2 hereditary breast cancer

W. Jin, Z. Shao, G. Di, 2012, Breast Cancer Research and Treatment.

Enriched variations in TEKT4 and breast cancer resistance to paclitaxel

Keda Yu, Z. Shao, Guangyu Liu, 2014, Nature Communications.

O-GlcNAcylation of MORC2 at threonine 556 by OGT couples TGF-β signaling to breast cancer progression

Z. Shao, Da-Qiang Li, Ying-Ying Liu, 2022, Cell Death & Differentiation.

Spatiotemporal Patterns of Loco-Regional Recurrence After Breast-Conserving Surgery

Junjie Li, Keda Yu, Z. Shao, 2021, Frontiers in Oncology.

AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2– advanced breast cancer

A. Bardia, H. Iwata, Z. Shao, 2022, Therapeutic advances in medical oncology.

Concurrent neoadjuvant chemotherapy and estrogen deprivation in patients with estrogen receptor–positive, human epidermal growth factor receptor 2–negative breast cancer (CBCSG‐036): A randomized, controlled, multicenter trial

Hong-wei Zhang, L. Fan, Keda Yu, 2019, Cancer.

Predictive and prognostic value of Matrix metalloproteinase (MMP) - 9 in neoadjuvant chemotherapy for triple-negative breast cancer patients

Z. Shao, Sheng Chen, Ruo-Xi Wang, 2018, BMC Cancer.

Comprehensive metabolomics expands precision medicine for triple-negative breast cancer

Fan Yang, Xin Hu, F. Bertucci, 2022, Cell Research.

Reduced Expression of TET1, TET2, TET3 and TDG mRNAs Are Associated with Poor Prognosis of Patients with Early Breast Cancer

Z. Shao, Yu Yang, Q. Hong, 2015, PloS one.

Functional variants in TNFAIP8 associated with cervical cancer susceptibility and clinical outcomes.

Menghong Sun, Q. Wei, Keda Yu, 2013, Carcinogenesis.

Protein Phosphatase 1 Subunit PPP1R14B Stabilizes STMN1 to Promote Progression and Paclitaxel Resistance in Triple-Negative Breast Cancer

Z. Shao, Da-Qiang Li, Fang-Lin Zhang, 2022, Cancer research.

Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial

Xin Hu, L. Fan, Z. Shao, 2022, Molecular cancer.

ALDH1A1 Activity in Tumor-Initiating Cells Remodels Myeloid-Derived Suppressor Cells to Promote Breast Cancer Progression

Z. Shao, Zuoren Yu, Botao Zhao, 2021, Cancer Research.

Toll-like receptor 3 -926T>A increased the risk of breast cancer through decreased transcriptional activity

L. Fan, Keda Yu, Z. Shao, 2019, Oncoimmunology.

Toll-like receptor 3 acts as a suppressor gene in breast cancer initiation and progression: a two-stage association study and functional investigation

L. Fan, Keda Yu, Z. Shao, 2019, Oncoimmunology.

Host genotype and tumor phenotype of chemokine decoy receptors integrally affect breast cancer relapse

Keda Yu, Z. Shao, Xiao-hua Zeng, 2015, Oncotarget.

Difference between observed and expected number of involved lymph nodes reflects the metastatic potential of breast cancer independent to intrinsic subtype

Keda Yu, Z. Shao, Yizhou Jiang, 2015, Oncotarget.

Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients

Z. Shao, Guangyu Liu, Jiong Wu, 2009, Breast Cancer Research and Treatment.

Effect of radiotherapy on survival of women with locally excised ductal carcinoma in situ of the breast: a Surveillance, Epidemiology, and End Results population-based analysis

Keda Yu, Z. Shao, Zheng Wang, 2015, OncoTargets and therapy.

Estrogen receptor‐negative breast cancer cells transfected with the estrogen receptor exhibit increased RARα gene expression and sensitivity to growth inhibition by retinoic acid

Z. Shao, M. Sheikh, Z. Shao, 1993, Journal of cellular biochemistry.

Impact of hormone receptor status and distant recurrence-free interval on survival benefits from trastuzumab in HER2-positive metastatic breast cancer

Xin Hu, Z. Shao, Jian Zhang, 2017, Scientific Reports.

Association between delayed initiation of adjuvant CMF or anthracycline-based chemotherapy and survival in breast cancer: a systematic review and meta-analysis

Keda Yu, Z. Shao, Guangyu Liu, 2013, BMC Cancer.

Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial

Xin Hu, Z. Shao, Xiaoyu Zhu, 2020, Cell Research.

Unfavourable clinicopathologic features and low response rate to systemic adjuvant therapy: results with regard to poor survival in young Chinese breast cancer patients

Z. Shao, G. Di, W. Yin, 2010, Breast Cancer Research and Treatment.

Genetic contribution of GADD45A to susceptibility to sporadic and non-BRCA1/2 familial breast cancers: a systematic evaluation in Chinese populations

L. Fan, Keda Yu, Z. Shao, 2010, Breast Cancer Research and Treatment.

Estrogen receptor‐low breast cancer: Biology chaos and treatment paradox

Keda Yu, Z. Shao, R. Shui, 2021, Cancer communications.

A recessive variant of XRCC4 predisposes to non-BRCA1/2 breast cancer in chinese women and impairs the DNA damage response via dysregulated nuclear localization

Xin Hu, Q. Wei, Keda Yu, 2014, Oncotarget.

Fiberoptic ductoscopy for patients with nipple discharge

Z. Shao, Jiong Wu, S. Barsky, 2000, Cancer.

Integrated gene expression profile predicts prognosis of breast cancer patients

Z. Shao, W. Jin, Lian-fang Li, 2008, Breast Cancer Research and Treatment.

Models for predicting BRCA1 and BRCA2 mutations in Han Chinese familial breast and/or ovarian cancer patients

Wei Huang, Jiong Wu, Z. Shao, 2009, Breast Cancer Research and Treatment.

A functional polymorphism in the promoter region of GSTM1 implies a complex role for GSTM1 in breast cancer

L. Fan, Keda Yu, Z. Shao, 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

CASP7 variants modify susceptibility to cervical cancer in Chinese women

Menghong Sun, Q. Wei, Keda Yu, 2015, Scientific Reports.

Neo-adjuvant chemotherapy for operable breast cancer induces apoptosis

Z. Shao, S. Barsky, J. Fontana, 1999, Breast Cancer Research and Treatment.

XRCC2 Arg188His polymorphism is not directly associated with breast cancer risk: evidence from 37,369 subjects

L. Fan, Keda Yu, Z. Shao, 2010, Breast Cancer Research and Treatment.

Five common single nucleotide polymorphisms in the PALB2 gene and susceptibility to breast cancer in eastern Chinese population

W. Jin, Keda Yu, Z. Shao, 2010, Breast Cancer Research and Treatment.

Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer

W. Jin, Z. Shao, Jiong Wu, 2007, Breast Cancer Research.

Targeting ATAD3A-PINK1-mitophagy axis overcomes chemoimmunotherapy resistance by redirecting PD-L1 to mitochondria

Z. Shao, Yi Yang, X. Bian, 2023, Cell Research.

A multigenic study on breast cancer risk associated with genetic polymorphisms of ER Alpha, COMT and CYP19 gene in BRCA1/BRCA2 negative Shanghai women with early onset breast cancer or affected relatives

Z. Shao, Wei Huang, Zhen Hu, 2007, Journal of Cancer Research and Clinical Oncology.

Polymorphisms of the Interleukin 6 gene contribute to cervical cancer susceptibility in Eastern Chinese women

Menghong Sun, Q. Wei, Keda Yu, 2013, Human Genetics.

In vivo multidimensional CRISPR screens identify Lgals2 as an immunotherapy target in triple-negative breast cancer

Xin Hu, Z. Shao, G. Di, 2022, Science advances.

Molecular subtype can predict the response and outcome of Chinese locally advanced breast cancer patients treated with preoperative therapy.

Jiong Wu, Z. Shao, Jiong Wu, 2010, Oncology reports.

Prognostic Effect of Microenvironment Phenotype in Triple-Negative Breast Cancer: Biomarker Analysis of a Prospective Trial

Keda Yu, Z. Shao, D. Ma, 2021, Frontiers in Molecular Biosciences.

Weekly paclitaxel/carboplatin/trastuzumab therapy improves pathologic complete remission in aggressive HER2-positive breast cancers, especially in luminal-B subtype, compared with a once-every-3-weeks schedule.

Keda Yu, Z. Shao, Jiong Wu, 2013, The oncologist.

Impact of type 2 diabetes mellitus on the prognosis of early stage triple-negative breast cancer in People’s Republic of China

Z. Shao, Guangyu Liu, Jiong Wu, 2014, OncoTargets and therapy.

ER-Poor and HER2-Positive: A Potential Subtype of Breast Cancer to Avoid Axillary Dissection in Node Positive Patients after Neoadjuvant Chemo-Trastuzumab Therapy

Keda Yu, Z. Shao, Guangyu Liu, 2014, PloS one.

Tumor characteristics and the clinical outcome of invasive lobular carcinoma compared to infiltrating ductal carcinoma in a Chinese population

Z. Shao, Guangyu Liu, Jiong Wu, 2012, World Journal of Surgical Oncology.

A systematic review of the relationship between polymorphic sites in the estrogen receptor-beta (ESR2) gene and breast cancer risk

Chen Yang, L. Fan, Keda Yu, 2011, Breast Cancer Research and Treatment.

Caution regarding genotyping methodology for a tri-allelic polymorphism in the novel breast cancer susceptibility gene NQO2

L. Fan, Keda Yu, Z. Shao, 2009, Breast Cancer Research and Treatment.

High expression of TLR3 in triple-negative breast cancer predicts better prognosis—data from the Fudan University Shanghai Cancer Center cohort and tissue microarrays

L. Fan, Z. Shao, Wenjin Zhang, 2023, BMC Cancer.

Genetic variants in GSTM3 gene within GSTM4-GSTM2-GSTM1-GSTM5-GSTM3 cluster influence breast cancer susceptibility depending on GSTM1

L. Fan, Keda Yu, Z. Shao, 2010, Breast Cancer Research and Treatment.

Breast conservative therapy in east part of China: a retrospective cohort study

Z. Shao, Jiong Wu, G. Di, 2006, Journal of Cancer Research and Clinical Oncology.

GCH1 induces immunosuppression through metabolic reprogramming and IDO1 upregulation in triple-negative breast cancer

Xin Hu, Xiao-En Xu, Z. Shao, 2021, Journal for ImmunoTherapy of Cancer.

Comments on: a prediction model for distant metastasis after isolated locoregional recurrence of breast cancer

Junjie Li, Z. Shao, Feilin Qu, 2023, Breast Cancer Research and Treatment.

A Straightforward but Not Piecewise Relationship between Age and Lymph Node Status in Chinese Breast Cancer Patients

Junjie Li, Keda Yu, Z. Shao, 2010, PloS one.

The immunohistochemically “ER-negative, PR-negative, HER2-negative, CK5/6-negative, and HER1-negative” subgroup is not a surrogate for the normal-like subtype in breast cancer

Keda Yu, Z. Shao, Z. Shen, 2009, Breast Cancer Research and Treatment.

Mixed invasive ductal and lobular carcinoma has distinct clinical features and predicts worse prognosis when stratified by estrogen receptor status

Yi Xiao, Ding Ma, Z. Shao, 2017, Scientific Reports.

Progesterone receptor status provides predictive value for adjuvant endocrine therapy in older estrogen receptor-positive breast cancer patients.

Keda Yu, Z. Shao, Guangyu Liu, 2007, Breast.

Clinicopathologic characteristics at diagnosis and the survival of patients with medullary breast carcinoma in China: a comparison with infiltrating ductal carcinoma-not otherwise specified

Z. Shao, G. Di, A. Cao, 2013, World Journal of Surgical Oncology.

Hazard of breast cancer-specific mortality among women with estrogen receptor-positive breast cancer after five years from diagnosis: implication for extended endocrine therapy.

Keda Yu, Z. Shao, Jiong Wu, 2012, The Journal of clinical endocrinology and metabolism.

Downregulation of transgelin 2 promotes breast cancer metastasis by activating the reactive oxygen species/nuclear factor-κB signaling pathway

Z. Shao, Guangyu Liu, Jiong Wu, 2019, Molecular medicine reports.

Adjuvant Therapy of Breast Cancer with Pirarubicin Versus Epirubicin in Combination with Cyclophosphamide and 5‐fluorouracil

Junjie Li, Keda Yu, Z. Shao, 2011, The breast journal.

O-GlcNAcylation of MORC2 at threonine 556 by OGT couples TGF-β signaling to breast cancer progression

Z. Shao, Guangyu Liu, Da-Qiang Li, 2022, Cell death and differentiation.

Copy number amplification of ENSA promotes the progression of triple-negative breast cancer via cholesterol biosynthesis

Keda Yu, Z. Shao, Jin-Yu Ge, 2022, Nature Communications.

Polymorphisms of the Interleukin 6 gene contribute to cervical cancer susceptibility in Eastern Chinese women

Menghong Sun, Keda Yu, Z. Shao, 2012, Human Genetics.

Identification and characterization of two novel germ line p53 mutations in the non-LFS/non-LFL breast cancer families in Chinese population

W. Jin, Z. Shao, G. Di, 2009, Breast Cancer Research and Treatment.

Superenhancer drives a tumor-specific splicing variant of MARCO to promote triple-negative breast cancer progression

Z. Shao, G. Di, Shenglin Huang, 2022, Proceedings of the National Academy of Sciences of the United States of America.

CCL19+ dendritic cells potentiate clinical benefit of anti-PD-(L)1 immunotherapy in triple-negative breast cancer.

Z. Shao, Li Chen, Yizhou Jiang, 2023, Med.

Deep Learning-Based Microcalcification Detection and Classification of Mammography for Diagnosis of Breast Cancer

Yan Huang, Keda Yu, Z. Shao, 2022, SSRN Electronic Journal.

Comments on: The clinical relevance of various methods of classifying ipsilateral breast tumor recurrence as either true local recurrence or new primary

Junjie Li, Z. Shao, Feilin Qu, 2022, Breast Cancer Research and Treatment.

Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial

Junjie Li, Keda Yu, Z. Shao, 2023, Cell Research.

High expression of metabolic enzyme PFKFB4 is associated with poor prognosis of operable breast cancer

Xin Hu, Z. Shao, Z. Cao, 2019, Cancer Cell International.

Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial

Xin Hu, L. Fan, Z. Shao, 2022, Molecular Cancer.

The associations between two polymorphisms in the interleukin-10 gene promoter and breast cancer risk

L. Fan, Keda Yu, Z. Shao, 2010, Breast Cancer Research and Treatment.

SCUBE2 mediates bone metastasis of luminal breast cancer by modulating immune-suppressive osteoblastic niches

Z. Shao, G. Hu, Qifeng Yang, 2023, Cell Research.

The two faces of autophagy and the pathological underestimation of DCIS

Keda Yu, Z. Shao, 2011, Nature Reviews Cancer.

Integrated analysis reveals prognostic value of HLA-I LOH in triple-negative breast cancer

Z. Shao, G. Di, Yizhou Jiang, 2021, Journal for ImmunoTherapy of Cancer.

Invasive micropapillary carcinoma of the breast had no difference in prognosis compared with invasive ductal carcinoma: a propensity-matched analysis

Keda Yu, Z. Shao, Jingping Peng, 2019, Scientific Reports.

[CHEK2 c.1100delC may not contribute to genetic background of hereditary breast cancer from Shanghai of China].

Z. Shao, G. Di, Wei Huang, 2006, Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics.

Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials

Bingshu E. Chen, R. Gray, P. Lønning, 2023, The Lancet.

Association of adjuvant aromatase inhibitor with cataract risk in postmenopausal women with breast cancer

Keda Yu, Z. Shao, Han Chen, 2020, Annals of translational medicine.

ESR1 gene amplification: another mechanism regulating the cellular levels of ERα

Keda Yu, Z. Shao, 2011, Nature Reviews Cancer.

De‐escalation of five‐year adjuvant endocrine therapy in patients with estrogen receptor‐low positive (immunohistochemistry staining 1%‐10%) breast cancer: Propensity‐matched analysis from a prospectively maintained cohort

Keda Yu, Z. Shao, Yu-Wen Cai, 2022, Cancer.

Effect of Genetic Variants in Two Chemokine Decoy Receptor Genes, DARC and CCBP2, on Metastatic Potential of Breast Cancer

L. Fan, Keda Yu, Z. Shao, 2013, PloS one.

ERbeta exerts multiple stimulative effects on human breast carcinoma cells.

Jiong Wu, Z. Shao, Jiong Wu, 2004, Oncogene.

Breast conserving therapy in stage T1 & T2 breast cancer patients

Z. Shao, Jiong Wu, G. Di, 2005 .

Association between delayed initiation of adjuvant CMF or anthracycline-based chemotherapy and survival in breast cancer: a systematic review and meta-analysis

Keda Yu, Z. Shao, Guangyu Liu, 2013, BMC Cancer.

Interaction between glutathione S‐transferase M1‐null/present polymorphism and adjuvant chemotherapy influences the survival of breast cancer

Keda Yu, Z. Shao, Qiang Zhang, 2018, Cancer medicine.

The Effect of Laterality and Primary Tumor Site on Cancer-Specific Mortality in Breast Cancer: A SEER Population-Based Study

Keda Yu, Z. Shao, G. Di, 2014, PloS one.

Taxanes directly induce T cell cytotoxic extracellular vesicles to eradicate tumor cells.

Z. Shao, Yi Xiao, Ying Xu, 2023, Cancer cell.

In vivo CRISPR screens identify RhoV as a pro‐metastasis factor of triple‐negative breast cancer

Xin Hu, Z. Shao, Y. Gong, 2023, Cancer science.

Calcifications in triple-negative breast cancer: Molecular features and treatment strategies

Z. Shao, G. Di, X. Jin, 2023, NPJ breast cancer.

TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer.

Darlington S. Mapiye, D. Cescon, Z. Shao, 2023, Future oncology.

Retinoid-resistant estrogen receptor-negative human breast carcinoma cells transfected with retinoic acid receptor-alpha acquire sensitivity to growth inhibition by retinoids.

Z. Shao, B. Conley, M. Sheikh, 1994, The Journal of biological chemistry.

Humatrix, a novel myoepithelial matrical gel with unique biochemical and biological properties.

Z. Shao, S. Barsky, Z. Shao, 1998, Cancer letters.

Cathepsin D as a prognostic indicator for node-negative breast cancer patients using both immunoassays and enzymatic assays.

Z. Shao, Z. Shao, L. Case, 1992, Cancer research.

The human myoepithelial cell is a natural tumor suppressor.

Z. Shao, S. Barsky, Z. Shao, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

The Use of Oxytocin in Nipple Fluid Aspiration

R. Elashoff, Z. Shao, Liping Zhang, 2003, The breast journal.

The role of the breast ductal system in the diagnosis of cancer (review).

Z. Shao, M. Nguyen, Y. Liu, 2001, Oncology Report.

Clinical feasibility and oncological safety of non-radioactive targeted axillary dissection after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: a prospective diagnostic and prognostic study

Kairui Jin, Junjie Li, Z. Shao, 2023, International journal of surgery.

Genetic matters of CYP2D6 in breast cancer: copy number variations and nucleotide polymorphisms

Keda Yu, Z. Shao, 2009, Nature Reviews Cancer.

Genistein exerts multiple suppressive effects on human breast carcinoma cells.

Z. Shao, Jiong Wu, S. Barsky, 1998, Cancer research.

Molecular features and clinical implications of the heterogeneity in Chinese patients with HER2-low breast cancer

Z. Shao, Yizhou Jiang, D. Ma, 2023, Nature communications.

ABT-737 reverses the acquired radioresistance of breast cancer cells by targeting Bcl-2 and Bcl-xL

W. Jin, Z. Shao, Qing Yang, 2012, Journal of experimental & clinical cancer research : CR.

The human myoepithelial cell exerts antiproliferative effects on breast carcinoma cells characterized by p21WAF1/CIP1 induction, G2/M arrest, and apoptosis.

Z. Shao, S. Barsky, Z. Shao, 1998, Experimental cell research.

MicroRNA-200a confers chemoresistance by antagonizing TP53INP1 and YAP1 in human breast cancer

Z. Shao, G. Di, Q. Hong, 2018, BMC Cancer.

Inflammatory response-based subtyping and potential therapeutic strategies for triple-negative breast cancer

Z. Shao, Jiong Wu, Ze-qing Li, 2023, Reproductive and Developmental Medicine.

Nab-paclitaxel Followed by Dose-dense Epirubicin/Cyclophosphamide in Neoadjuvant Chemotherapy for Triple-negative Breast Cancer: A Phase II Study

L. Fan, Z. Shao, Y. Liu, 2022, The oncologist.

Prediction of axillary lymph node metastasis in triple-negative breast cancer by multi-omics analysis and an integrated model

Z. Shao, D. Ma, Yu-Wei Li, 2021, Annals of Translational Medicine.

Thyroid hormone enhancement of estradiol stimulation of breast carcinoma proliferation.

Z. Shao, M. Sheikh, A. Rishi, 1995, Experimental cell research.

Combining accurate genetic and clinical information in breast cancer risk model

Keda Yu, Z. Shao, Q. Fang, 2011, Breast Cancer Research and Treatment.

Emerging Therapeutic Targets for Cancer Metastasis: From the Perspective of Embryo Implantation

Z. Shao, Z. Shao, D-Q Li, 2017 .

Is RAD51 135G>C polymorphism really associated with breast cancer in general population? Biased design and results lead to inappropriate conclusion

Keda Yu, Z. Shao, Ying-Feng Zhou, 2011, Breast Cancer Research and Treatment.

The prevalence of BRCA1 and BRCA2 mutations in eastern Chinese women with breast cancer

Z. Shao, Jiong Wu, Wei Huang, 2006, Journal of Cancer Research and Clinical Oncology.

Altered mucin expression is a field change that accompanies mucinous (colloid) breast carcinoma histogenesis.

Z. Shao, S. Barsky, Z. Shao, 1998, Human pathology.

Low level of ARID1A contributes to adaptive immune resistance and sensitizes triple‐negative breast cancer to immune checkpoint inhibitors

Z. Shao, Shenglin Huang, Yu Yang, 2023, Cancer communications.

Enhanced Expression of Rab27A Gene by Breast Cancer Cells Promoting Invasiveness and the Metastasis Potential by Secretion of Insulin-Like Growth Factor-II

Z. Shao, Z. Shen, F. Wang, 2008, Molecular Cancer Research.

A prospective, multicenter, controlled, observational study to evaluate the efficacy of a patient support program in improving patients’ persistence to adjuvant aromatase inhibitor medication for postmenopausal, early stage breast cancer

Hong-wei Zhang, Jin-hai Tang, Keda Yu, 2012, Breast Cancer Research and Treatment.

Oncotargets and Therapy Dovepress Dovepress Effect of Radiotherapy on Survival of Women with Locally Excised Ductal Carcinoma in Situ of the Breast: a Surveillance, Epidemiology, and End Results Population-based Analysis

Keda Yu, Z. Shao, Zheng Wang, 2022 .

MicroRNA-200a Promotes Anoikis Resistance and Metastasis by Targeting YAP1 in Human Breast Cancer

Z. Shao, Jiong Wu, G. Di, 2013, Clinical Cancer Research.

Abstract OT1-03-05: TROPION-Breast02: Phase 3, open-label, randomized study of first-line datopotamab deruxtecan versus chemotherapy in patients with locally recurrent inoperable or metastatic TNBC who are not candidates for anti-PD-(L)1 therapy

Darlington S. Mapiye, D. Cescon, Z. Shao, 2023, Cancer Research.

Ipsilateral breast tumor recurrence after breast-conserving surgery: insights into biology and treatment

Junjie Li, Z. Shao, Songyang Wu, 2023, Breast Cancer Research and Treatment.

Neoadjuvant Pseudomonas aeruginosa mannose-sensitive hemagglutinin (PA-MSHA) and chemotherapy versus placebo plus chemotherapy in patients with HER2-negative breast cancer: a randomized, controlled, double-blind trial

Keda Yu, Z. Shao, Jiong Wu, 2023, Annals of translational medicine.

Artificial intelligence-based diagnosis of breast cancer by mammography microcalcification

Yan Huang, Keda Yu, Z. Shao, 2023, Fundamental Research.

Enriched variations in TEKT4 and breast cancer resistance to paclitaxel

Keda Yu, Z. Shao, Guangyu Liu, 2014, Nature Communications.

Regulation of the human retinoic acid receptor alpha gene in the estrogen receptor negative human breast carcinoma cell lines SKBR-3 and MDA-MB-435.

Z. Shao, X. -. Li, A. Rishi, 1996, Cancer research.

N-(4-hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma.

Z. Shao, B. Conley, M. Sheikh, 1995, Carcinogenesis.